Citigroup Inc An2 Therapeutics, Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.93 - $3.76 $63,535 - $123,779	-32,920 Reduced 46.49%	37,887 $81,000
Q1 2024 May 10, 2024	SELL	$2.78 - $21.53 $249,307 - $1.93 Million	-89,679 Reduced 55.88%	70,807 $230,000
Q4 2023 Feb 09, 2024	BUY	$13.92 - $21.0 $19,223 - $29,001	1,381 Added 0.87%	160,486 $3.29 Million
Q3 2023 Nov 09, 2023	BUY	$7.58 - $16.08 $186,710 - $396,082	24,632 Added 18.32%	159,105 $2.56 Million
Q1 2023 May 11, 2023	SELL	$7.94 - $15.6 $595 - $1,170	-75 Reduced 0.06%	134,473 $1.33 Million
Q4 2022 Feb 09, 2023	BUY	$8.51 - $19.69 $25 - $59	3 Added 0.0%	134,548 $1.28 Million
Q3 2022 Nov 10, 2022	BUY	$7.61 - $22.29 $355,919 - $1.04 Million	46,770 Added 53.28%	134,545 $2.34 Million
Q2 2022 Aug 10, 2022	BUY	$7.7 - $18.82 $675,867 - $1.65 Million	87,775 New	87,775 $680,000

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $26M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.